Friday, 15 Nov 2019

You are here

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids (CS) are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab (RTX) may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

A minority of HSP cases are so severe with either persistent rash, arthritis, abdominal involvement, or renal disease, that CS are needed. Other alternatives for steroid sparing are few.

Crayne et al describes 8 children treated with RTX for chronic refractory HSP.  Patients were identified by retrospective review of data between 2006–2014 at a single institution.

Prior to RTX, 7/8 had at least one hospitalization for HSP (median 1.5, range 0–3).

Following RTX, only 2/8 were hospitalized.  With RTX use, oral CS use fell significantly from 0.345 mg/kg/day before RTX to 0 mg/kg/day at 6 months (p = 0.078), 1 year (p = 0.0625), and 2 years (p = 0.03) following RTX infusion.

Ultimately 7/8 remission criteria (no active rash, arthritis, nephritis (hematuria or proteinuria), or gastrointestinal involvement). 

The authors also describe another eight, mostly single case, reports of RTX use in adults and children with HSP - all with beneficial outcomes. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.